The research project entitled “Using MYC inhibition to overcome immunotherapy resistance in KRAS-driven NSCLC with diverse mutational profiles (MYCombIO)” with reference PLEC2021-007959 is funded by MCIN/AEI /10.13039/501100011033 and by the European Union NextGenerationEU/ PRTR

It represents funding of 1.335.512,30€ euros over 3 years (2021-2024), distributed between Peptomyc (377.537€ loan), the Vall d’Hebron Institute of Oncology (399.771€ grant), the Fundación para la Investigación Médica Aplicada (268.098€ grant) and the Fundación para la Investigación Biomédica del Hospital Universitario Doce de Octubre (270233€ grant), which are joining forces for this project.

This is a very significant round of funding and further shows the strong support for this project both within Spain and the European Commission. This project aims to validate the use of MYC inhibition in KRAS mutant Non-Small Cell Lung Cancer (NSCLC) with concomitant mutations in the most common tumor suppressor genes, and its use to overcome, or potentially prevent, immunotherapeutic resistance in these tumor entities.